Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Sells $211,477.86 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 5,742 shares of Scholar Rock stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $211,477.86. Following the completion of the sale, the general counsel now directly owns 189,295 shares of the company’s stock, valued at approximately $6,971,734.85. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Junlin Ho also recently made the following trade(s):

• On Thursday, January 16th, Junlin Ho sold 9,039 shares of Scholar Rock stock. The stock was sold at an average price of $44.20, for a total transaction of $399,523.80.

Scholar Rock Stock Down 3.7 %

SRRK opened at $37.70 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The firm’s fifty day moving average is $41.81 and its 200 day moving average is $28.51. The stock has a market cap of $3.53 billion, a price-to-earnings ratio of -16.04 and a beta of 0.50.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Mackenzie Financial Corp purchased a new position in shares of Scholar Rock during the 4th quarter valued at $212,000. GF Fund Management CO. LTD. purchased a new position in shares of Scholar Rock during the 4th quarter valued at $85,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Scholar Rock during the 4th quarter valued at $16,680,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Scholar Rock by 42.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,231 shares of the company’s stock valued at $5,845,000 after buying an additional 40,436 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its stake in shares of Scholar Rock by 317.4% during the 4th quarter. Voloridge Investment Management LLC now owns 201,576 shares of the company’s stock valued at $8,712,000 after buying an additional 153,280 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SRRK shares. HC Wainwright boosted their price objective on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Wedbush reissued an “outperform” rating and set a $47.00 price objective on shares of Scholar Rock in a research report on Wednesday, January 29th. Finally, Truist Financial boosted their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.